Poland
· Delayed Price · Currency is PLN Genomtec Statistics
Total Valuation
Genomtec has a market cap or net worth of PLN 97.14 million. The enterprise value is 85.45 million.
| Market Cap | 97.14M |
| Enterprise Value | 85.45M |
Important Dates
The last earnings date was Thursday, May 29, 2025.
| Earnings Date | May 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Genomtec has 13.32 million shares outstanding. The number of shares has increased by 14.90% in one year.
| Current Share Class | 13.32M |
| Shares Outstanding | 13.32M |
| Shares Change (YoY) | +14.90% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.17% |
| Owned by Institutions (%) | 5.56% |
| Float | 10.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16,189.35 |
| PB Ratio | 6.40 |
| P/TBV Ratio | 10.05 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -7.27 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.08, with a Debt / Equity ratio of 0.14.
| Current Ratio | 3.08 |
| Quick Ratio | 2.90 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -893.38 |
Financial Efficiency
Return on equity (ROE) is -112.95% and return on invested capital (ROIC) is -58.46%.
| Return on Equity (ROE) | -112.95% |
| Return on Assets (ROA) | -35.31% |
| Return on Invested Capital (ROIC) | -58.46% |
| Return on Capital Employed (ROCE) | -61.94% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 26 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.14% in the last 52 weeks. The beta is 0.24, so Genomtec's price volatility has been lower than the market average.
| Beta (5Y) | 0.24 |
| 52-Week Price Change | -36.14% |
| 50-Day Moving Average | 7.57 |
| 200-Day Moving Average | 7.77 |
| Relative Strength Index (RSI) | 46.02 |
| Average Volume (20 Days) | 22,547 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Genomtec had revenue of PLN 6,000 and -11.76 million in losses. Loss per share was -0.81.
| Revenue | 6,000 |
| Gross Profit | -634,000 |
| Operating Income | -11.61M |
| Pretax Income | -11.70M |
| Net Income | -11.76M |
| EBITDA | -9.29M |
| EBIT | -11.61M |
| Loss Per Share | -0.81 |
Balance Sheet
The company has 13.84 million in cash and 2.16 million in debt, giving a net cash position of 11.68 million or 0.88 per share.
| Cash & Cash Equivalents | 13.84M |
| Total Debt | 2.16M |
| Net Cash | 11.68M |
| Net Cash Per Share | 0.88 |
| Equity (Book Value) | 15.17M |
| Book Value Per Share | 1.04 |
| Working Capital | 10.72M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | -193,566.67% |
| Pretax Margin | -195,016.67% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Genomtec does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14.90% |
| Shareholder Yield | n/a |
| Earnings Yield | -12.10% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |